Future studies of LJM716 will also evaluate LJM716 in combination with other therapeutic agents, including the PI3K inhibitor alpelisib (BYL719) in patients with ESCC, and as part of the triple combination of LJM716, alpelisib, and trastuzumab in patients with HER2-overexpressing breast cancer, in which preliminary data have indicated antitumor activity in patients with PIK3CA mutations [24]. This evidence concerns the gene PIK3CA and esophageal squamous cell carcinoma.